공시 • May 06
Twist Bioscience Corporation Expands Clonal Genes Offering to Include Long and Complex Sequences Twist Bioscience Corporation had expanded its clonal genes portfolio with the early access launch of Complex Genes. Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products. Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics. Sequences with complex elements have historically been difficult to produce at commercial scale. Leveraging its proprietary silicon-based DNA synthesis platform and improved downstream processes in manufacturing, automation, and sequencing, Twist can now reliably synthesize and deliver these previously out-of-reach complex sequences at scale. Complex sequence elements such as short tandem, inverted and long repeats, as well as high or low GC content and more, can be essential components of customers’ sequences in the development of nucleic acid therapeutics such as cell and gene therapies, mRNA therapies and more. The ability to synthesize complex sequences is also essential for AI-enabled drug discovery where researchers need their AI-generated sequences manufactured exactly, without adding a step to alter the sequences for manufacturability. By delivering genes with novel and complex structures combined with a transparent online ordering and tracking process, Twist enables customers to advance cutting edge research, empowering the development of new and next-generation therapeutics. Twist can synthesize and deliver complex sequences including short tandem repeats, inverted repeats, long repeats, homopolymers up to 30 base pairs and localized regions of high or low GC content. These are features commonly found in sequence elements such as advanced promoters, UTRs, ITRs, secondary structures and GS linkers. When customers submit sequences, they will receive a complexity score and a manufacturability score, for full transparency during the ordering process. Twist reliably delivers constructs ranging from 300 to 7,000 base pairs within 15 business days standard turnaround time, regardless of order scale or complexity. All Twist Clonal Genes can be cloned into a Twist catalog vector, or an onboarded vector of the customer’s choice. Reported Earnings • May 05
Second quarter 2026 earnings released: US$0.71 loss per share (vs US$0.66 loss in 2Q 2025) Second quarter 2026 results: US$0.71 loss per share (further deteriorated from US$0.66 loss in 2Q 2025). Revenue: US$110.7m (up 19% from 2Q 2025). Net loss: US$44.0m (loss widened 12% from 2Q 2025). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. 공시 • Apr 21
Twist Bioscience Corporation to Report Q2, 2026 Results on May 04, 2026 Twist Bioscience Corporation announced that they will report Q2, 2026 results Pre-Market on May 04, 2026 Recent Insider Transactions • Feb 24
Insider recently sold €1.7m worth of stock On the 17th of February, Paula Green sold around 39k shares on-market at roughly €44.30 per share. This transaction amounted to 55% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €10m more than they bought in the last 12 months. 공시 • Feb 10
Twist Bioscience Corporation Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes Twist Bioscience Corporation launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist's library preparation portfolio, with advantages enabled by Twist in-house developed enzymes, including a previously developed ligase as well as a newly developed polymerase. Engineered for next generation sequencing applications, the specialized TrueAmp polymerase maximizes coverage across typically hard-to- sequence regions of the genome, while maintaining high accuracy during DNA copying. The kit ensures high yields even from low- input or degraded starting samples, which minimizes amplification-introduced errors and results in more usable high-quality data. To streamline large-scale workflows, the Twist TrueAmp Library Prep kit has been validated with the Twist HT-UDI adapters system, allowing for up to 3,072 unique indexes as well as Twist UMI adapters, ensuring precise strand identification and efficient multiplexing. To serve customers across sequencing applications, Twist developed a complementary PCR-free version of the kit for researchers conducting whole genome sequencing (WGS). Leveraging Twist's engineered ligase, the Twist PCR-Free WGS library Preparation Kit efficiently converts starting DNA without bias commonly seen in whole genome sequencing. Precly optimized enzymatic fragmentation conditions deliver consistent outputs that maximize sequencing efficiency and improve data quality. The PCR-Free WGS Kit allows Twist to further serve customers using whole genome sequencing for approaches where low pass sequencing is sufficient, such as rare disease, while in parallel providing researchers working in areas that require deep sequencing, such as cancer, with panels and other tools to support their research. Recent Insider Transactions • Feb 08
VP & Chief Accounting Officer recently sold €278k worth of stock On the 4th of February, Robert Werner sold around 7k shares on-market at roughly €38.72 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €8.7m more than they bought in the last 12 months. 
